GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
(2007) In Current Diabetes Reports 7(5). p.340-347- Abstract
- Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1021637
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Diabetes Reports
- volume
- 7
- issue
- 5
- pages
- 340 - 347
- publisher
- Current Science, Inc.
- external identifiers
-
- pmid:18173966
- scopus:36749042536
- ISSN
- 1539-0829
- language
- English
- LU publication?
- yes
- id
- a318cac6-ff4f-4d44-92ed-a80f7400056c (old id 1021637)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18173966?dopt=Abstract
- date added to LUP
- 2016-04-04 08:39:23
- date last changed
- 2024-10-12 18:22:17
@article{a318cac6-ff4f-4d44-92ed-a80f7400056c, abstract = {{Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.}}, author = {{Ahrén, Bo}}, issn = {{1539-0829}}, language = {{eng}}, number = {{5}}, pages = {{340--347}}, publisher = {{Current Science, Inc.}}, series = {{Current Diabetes Reports}}, title = {{GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.}}, url = {{http://www.ncbi.nlm.nih.gov/pubmed/18173966?dopt=Abstract}}, volume = {{7}}, year = {{2007}}, }